Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nanjing Immunophage Biotech Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter defines the current workload for the company's patent prosecution efforts. The focus on this specific technology area indicates a specialized research and development path for the organization as it seeks to protect its innovations.
The prosecution landscape is highly concentrated, involving 1 distinct examiner and 1 distinct art unit. This level of focus means that the company's entire pending portfolio is subject to the review of a single administrative entity. Such a narrow distribution simplifies the coordination of legal arguments across the portfolio and allows for a unified response strategy.
LEE, ANDREW P serves as the busiest examiner for the company, with 1 busiest examiner pending action. Monitoring the specific preferences and past decisions of this individual is a critical component of the current prosecution strategy. The progress of this specific case will significantly impact the overall timeline for the portfolio's development.
Operating within 1 distinct art unit allows for a very targeted strategy that accounts for the specific nuances of that unit's interpretation of biotechnology patent law. The 1 pending office action represents the entirety of the company's current interaction with the patent office, making the outcome of this case significant for the overall Biotechnology & Pharmaceuticals portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288793 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18288793 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Immunophage Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrew P Lee has the most, with 1 of Nanjing Immunophage Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
